

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.9850 • EQT FUND MANAGEMENT / SCHÜLKE & MAYR

SECTION 1.2

Description of the concentration

By virtue of the notified concentration, the investment fund EQT VIII (“**EQT VIII**”) (controlled by EQT Fund Management S.à r.l.) intends to indirectly acquire sole control over Schülke & Mayr GmbH and its subsidiaries (“**Schülke**”) within the meaning of Article 3(1)(b) of the EU Merger Regulation.

EQT VIII was launched in 2018 with commitments of approx. EUR 10.9 billion. The fund seeks to make investments primarily in Northern Europe. EQT VIII is part of the EQT group of private equity funds, ultimately owned by EQT AB headquartered in Sweden.

Schülke, headquartered in Germany, is active in infection prevention and hygiene and develops, produces and distributes antiseptics, disinfectants and personal care preservatives worldwide.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.